-
Je něco špatně v tomto záznamu ?
Prognostic Value of Tumor Tissue Up-regulated microRNAs in Clear Cell Renal Cell Carcinoma (ccRCC)
M. Pesta, I. Travnicek, V. Kulda, P. Ostasov, J. Windrichova, K. Houfkova, T. Knizkova, B. Bendova, O. Hes, M. Hora, O. Topolcan, J. Polivka
Jazyk angličtina Země Řecko
Typ dokumentu časopisecké články
NLK
PubMed Central
od 2017
Europe PubMed Central
od 2017
Open Access Digital Library
od 2004-01-01
PubMed
38936941
DOI
10.21873/invivo.13631
Knihovny.cz E-zdroje
- MeSH
- dospělí MeSH
- Kaplanův-Meierův odhad MeSH
- karcinom z renálních buněk * genetika patologie mortalita metabolismus MeSH
- lidé středního věku MeSH
- lidé MeSH
- mikro RNA * genetika MeSH
- nádorové biomarkery * genetika MeSH
- nádory ledvin * genetika patologie mortalita metabolismus MeSH
- prognóza MeSH
- regulace genové exprese u nádorů * MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- staging nádorů MeSH
- stanovení celkové genové exprese * MeSH
- upregulace MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND/AIM: The management of patients with clear cell renal cell carcinoma (ccRCC) includes prognosis assessment based on TNM classification and biochemical markers. This approach stratifies patients with advanced ccRCC into groups of favorable, intermediate, and poor prognosis. The aim of the study was to improve prognosis estimation using microRNAs involved in the pathogenesis of ccRCC. PATIENTS AND METHODS: The study was based on a histologically-verified set of matched ccRCC FFPE tissue samples (normal renal tissue, primary tumor, metastasis, n=20+20+20). The expression of 2,549 microRNAs was analyzed using the SurePrint G3 Human miRNA microarray kit (Agilent Technologies). Prognostic value of significantly deregulated microRNAs was further evaluated on microRNA expression and clinical data of 475 patients obtained from TCGA Kidney Clear Cell Carcinoma (KIRC) database. RESULTS: There were 13 up-regulated and 6 down-regulated microRNAs in tumor tissues compared to control tissues. Among them, survival analysis revealed those with prognostic significance. Patients with high expression of miR-21, miR-27a, miR-34a, miR-106b, miR-210, and miR-342 showed significantly unfavorable outcome. The opposite was observed for miR-30e, patients with low expression had significantly shorter survival. CONCLUSION: The inclusion of these microRNAs in a prognostic panel holds the potential to enhance stratification scoring systems, on which the treatment of ccRCC patients is based.
Biomedical Center Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic
Department of Biology Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic
Department of Pathology University Hospital in Pilsen Pilsen Czech Republic
Department of Urology University Hospital in Pilsen Pilsen Czech Republic
Laboratory of Immunoanalysis University Hospital in Pilsen Pilsen Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24013335
- 003
- CZ-PrNML
- 005
- 20240905134128.0
- 007
- ta
- 008
- 240725s2024 gr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.21873/invivo.13631 $2 doi
- 035 __
- $a (PubMed)38936941
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Pesta, Martin $u Department of Biology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic $u Laboratory of Immunoanalysis, University Hospital in Pilsen, Pilsen, Czech Republic
- 245 10
- $a Prognostic Value of Tumor Tissue Up-regulated microRNAs in Clear Cell Renal Cell Carcinoma (ccRCC) / $c M. Pesta, I. Travnicek, V. Kulda, P. Ostasov, J. Windrichova, K. Houfkova, T. Knizkova, B. Bendova, O. Hes, M. Hora, O. Topolcan, J. Polivka
- 520 9_
- $a BACKGROUND/AIM: The management of patients with clear cell renal cell carcinoma (ccRCC) includes prognosis assessment based on TNM classification and biochemical markers. This approach stratifies patients with advanced ccRCC into groups of favorable, intermediate, and poor prognosis. The aim of the study was to improve prognosis estimation using microRNAs involved in the pathogenesis of ccRCC. PATIENTS AND METHODS: The study was based on a histologically-verified set of matched ccRCC FFPE tissue samples (normal renal tissue, primary tumor, metastasis, n=20+20+20). The expression of 2,549 microRNAs was analyzed using the SurePrint G3 Human miRNA microarray kit (Agilent Technologies). Prognostic value of significantly deregulated microRNAs was further evaluated on microRNA expression and clinical data of 475 patients obtained from TCGA Kidney Clear Cell Carcinoma (KIRC) database. RESULTS: There were 13 up-regulated and 6 down-regulated microRNAs in tumor tissues compared to control tissues. Among them, survival analysis revealed those with prognostic significance. Patients with high expression of miR-21, miR-27a, miR-34a, miR-106b, miR-210, and miR-342 showed significantly unfavorable outcome. The opposite was observed for miR-30e, patients with low expression had significantly shorter survival. CONCLUSION: The inclusion of these microRNAs in a prognostic panel holds the potential to enhance stratification scoring systems, on which the treatment of ccRCC patients is based.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a karcinom z renálních buněk $x genetika $x patologie $x mortalita $x metabolismus $7 D002292
- 650 12
- $a mikro RNA $x genetika $7 D035683
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a regulace genové exprese u nádorů $7 D015972
- 650 12
- $a nádorové biomarkery $x genetika $7 D014408
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a nádory ledvin $x genetika $x patologie $x mortalita $x metabolismus $7 D007680
- 650 12
- $a stanovení celkové genové exprese $7 D020869
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a upregulace $7 D015854
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a Kaplanův-Meierův odhad $7 D053208
- 650 _2
- $a senioři nad 80 let $7 D000369
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Travnicek, Ivan $u Department of Urology, University Hospital in Pilsen, Pilsen, Czech Republic
- 700 1_
- $a Kulda, Vlastimil $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic; vlastimil.kulda@lfp.cuni.cz
- 700 1_
- $a Ostasov, Pavel $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
- 700 1_
- $a Windrichova, Jindra $u Laboratory of Immunoanalysis, University Hospital in Pilsen, Pilsen, Czech Republic $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
- 700 1_
- $a Houfkova, Katerina $u Department of Biology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
- 700 1_
- $a Knizkova, Tereza $u Department of Biology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
- 700 1_
- $a Bendova, Barbora $u Department of Urology, University Hospital in Pilsen, Pilsen, Czech Republic
- 700 1_
- $a Hes, Ondrej $u Department of Pathology, University Hospital in Pilsen, Pilsen, Czech Republic
- 700 1_
- $a Hora, Milan $u Department of Urology, University Hospital in Pilsen, Pilsen, Czech Republic
- 700 1_
- $a Topolcan, Ondrej $u Laboratory of Immunoanalysis, University Hospital in Pilsen, Pilsen, Czech Republic
- 700 1_
- $a Polivka, Jiri $u Laboratory of Immunoanalysis, University Hospital in Pilsen, Pilsen, Czech Republic $u Department of Histology and Embryology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
- 773 0_
- $w MED00175831 $t In Vivo $x 1791-7549 $g Roč. 38, č. 4 (2024), s. 1799-1805
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38936941 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240725 $b ABA008
- 991 __
- $a 20240905134122 $b ABA008
- 999 __
- $a ok $b bmc $g 2143257 $s 1225201
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 38 $c 4 $d 1799-1805 $e - $i 1791-7549 $m In Vivo $n In Vivo $x MED00175831
- LZP __
- $a Pubmed-20240725